Hsbc Holdings PLC Makes New Investment in AnaptysBio, Inc. $ANAB

Hsbc Holdings PLC acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 216,949 shares of the biotechnology company’s stock, valued at approximately $14,928,000.

Several other large investors have also bought and sold shares of ANAB. Persistent Asset Partners Ltd bought a new position in shares of AnaptysBio in the 2nd quarter worth approximately $39,000. Smartleaf Asset Management LLC boosted its position in shares of AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. grew its stake in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ANAB shares. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. TD Cowen decreased their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Scotiabank cut shares of AnaptysBio to a “hold” rating and set a $70.00 price target for the company. in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $80.00.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $57.29 on Friday. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The stock has a 50-day moving average of $58.57 and a 200 day moving average of $59.07. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -53.05 and a beta of 0.72.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.